Felt within 30-90 minutes; mild stimulation without the edge of caffeine; cognitive "clarity" rather than activation; lasts 4-6 hours.

• Acute (first hour): Faint warmth, mild tongue/teeth blue staining (sublingual), mood lift. Some users notice color/visual sharpening (real — MB modulates retinal mitochondrial function) within 30-90 minutes.
• Peak (1-3 hours): Subjective cognitive clarity; reduced mental fatigue; mood floor lifted slightly. Closer to ALCAR/astaxanthin in felt profile than to caffeine/modafinil. Not a stimulant; more an "I forgot less / faded less" effect.
• Taper (3-6 hours): Smooth decline, no rebound or crash typical. Some users report a mild headache 4-6 hours post-dose at higher (>50 mg) doses.
• Chronic (weeks 2-6): The "felt" effect tends to soften with daily use, but the mitochondrial / antioxidant effect is presumably cumulative. Many users prefer 5-on-2-off or every-other-day dosing to preserve subjective clarity.
• Variable: dose-sensitivity. Some users report best results at 5-10 mg sublingual (microdose); others at 30-50 mg; few report better effects above that range. The honest read: most subjective reports cluster at 10-50 mg, and going higher tends not to feel better. This is consistent with the biphasic hormesis curve.
• The blue tongue / blue urine / blue teeth thing is real and somewhat embarrassing. Sublingual MB stains the oral mucosa for 1-3 hours; the urine is bright cyan-green for 12-48 hours after a 30 mg dose. Sclera (whites of eyes) can take on a faint blue tint at higher doses. For Dylan in sales calls and on camera: not ideal. Some users dose at night to let the oral staining clear by morning, but the urine effect persists.

• Tolerance buildup: Pharmacological tolerance is minimal — the mitochondrial-bypass mechanism doesn't produce receptor downregulation. Subjective-effect tolerance is real — most users report the "felt" cognitive lift fades over 2-4 weeks of daily use, even though the underlying mitochondrial effect presumably continues.
• Recommended cycle: 5-on-2-off, or every-other-day. Some users do 2-weeks-on-1-week-off. Continuous daily use is pharmacologically fine but the staining and subjective-effect-fade favor cycling.
• Reset protocol: No taper required; no withdrawal. Discontinue at any time.

Synergistic with

• astaxanthin (Dylan's V5 plan, 6-12 mg AM): Strongly synergistic mechanistically. Astaxanthin is a membrane-spanning structural antioxidant; MB is a freely-distributed redox-active electron carrier. They protect different membrane compartments via different mechanisms. Both BBB-crossing. No documented interactions. Take both at breakfast with fish oil. No clinical trial of the combination exists — extrapolation only, but the mechanism layering is clean.
• idebenone (Dylan's V5 candidate, 90-180 mg with breakfast/lunch): Mechanistically complementary. Idebenone enters the ETC at complex III via NQO1 activation; MB acts as a parallel electron carrier bypassing both complex I and complex III. Different bypass routes, different activation pathways. In NQO1 low-activity carriers (rs1800566 T/T or C/T), MB may compensate for reduced idebenone responsiveness by routing electrons via the NQO1-independent path. Speculative but mechanistically coherent. Co-administer at breakfast.
• alcar (Dylan's V5 plan, 500 mg AM): Synergistic. ALCAR carries fatty acids into the mitochondrial matrix for β-oxidation; MB ensures the resulting electrons can be used downstream even if complex I/III function is suboptimal. Canonical mitochondrial cognitive layering.
• NAC (Dylan's V4, 1200 mg/day): Glutathione precursor; supports the cytoplasmic reducing environment that allows MB to cycle cleanly between MB+ and leucoMB. Already in V4 — synergistic without dose change.
• omega-3 / DHA (Dylan's V4 Carlson DHA Gems, 2 g): Membrane substrate that MB protects from peroxidation; lipid vehicle for absorption. Take at the same meal.
• SS-31 (elamipretide): Both are mitochondrial-membrane interventions but at different layers — SS-31 stabilizes cardiolipin / inner membrane structure; MB shuttles electrons across damaged complexes. Mechanism-complementary, no documented interaction. Not currently in Dylan's stack but on his watch list.
• MOTS-c / NAD+ precursors: Mitochondrial-axis interventions at different mechanism levels (biogenesis, cofactor pool, electron carrier). All three layer cleanly.
• modafinil (Dylan's V5 core): No documented serotonin-syndrome cases; modafinil is minimally serotonergic. Co-administration is not flagged in the literature. Watch for additive subjective stimulation in the first 1-2 weeks of co-administration.
• Curcumin (Dylan's V4 phytosome): Both have antioxidant + anti-inflammatory mechanisms. No documented interaction. Safe co-administration.
• Vitamin C / ascorbate: Reduces MB+ to leucoMB in vitro; oral co-administration is widely practiced and may shift MB toward the reduced (active electron-donor) form in tissue. Mechanism support is plausible; clinical relevance unclear.

Avoid stacking with

• SSRIs (fluoxetine, sertraline, escitalopram, paroxetine, citalopram, fluvoxamine): BLACK BOX-class contraindication. Serotonin-syndrome risk. FDA 2011 communication is unambiguous. Not currently in Dylan's stack; would be disqualifying if ever added.
• SNRIs (venlafaxine, duloxetine): Same risk class. Avoid.
• MAOIs (phenelzine, tranylcypromine, isocarboxazid): Additive MAO inhibition + serotonin syndrome risk. Avoid.
• Selegiline at MAO-A doses (>10 mg/day): Selegiline at low doses (1-2.5 mg/day) is MAO-B selective and theoretically lower-risk than SSRI co-admin, but the FDA warning is broad and co-administration of MB + selegiline is not advised. Dylan's V5 plan includes selegiline 1-2.5 mg/day as a potential add — this would force a choice between the two, or strict separation.
• Bupropion (Dylan's V5 contingency): Theoretical risk, lower than SSRIs but not zero. Bupropion is a weak DRI/NRI with negligible serotonergic activity at therapeutic doses; co-administration with MB is not flagged in major databases, but the FDA's broad warning language ("any serotonergic drug") would likely include it. If Dylan ever adds bupropion: stop MB.
• Triptans (sumatriptan, etc.): Serotonin-syndrome risk. Avoid.
• Tramadol, meperidine, fentanyl, methadone: Serotonergic opioids — avoid.
• Dextromethorphan (cough syrup): Serotonergic — avoid during MB use.
• St. John's Wort, 5-HTP, L-tryptophan (DYLAN'S V5 PRE-BED): Flag. L-Tryptophan at 1 g pre-bed is in Dylan's V5 plan as the glycine replacement. MAO-A inhibition + tryptophan loading is theoretically the classic recipe for serotonin syndrome. In practice, the tryptophan dose is small and the MB dose is 12-14 hours earlier (AM vs. pre-bed), so the kinetic separation is large. But: this is the single Dylan-stack interaction that needs the most explicit attention. If Dylan trials MB while on L-tryptophan, watch for any unusual evening agitation, hyperreflexia, or autonomic symptoms. Conservative move: trial MB without tryptophan first; reintroduce tryptophan after MB tolerance is established.
• Aggressive iron supplementation: Theoretical pro-oxidant interaction (iron + redox-active dye). Not clinically observed at biohacker doses. Not relevant for Dylan.

Neutral / safe co-administration

• All V4 stack items: NAC, citicoline, magnesium, phosphatidylserine, rhodiola, theanine, glycine (note: glycine is being replaced with tryptophan — see above), D3+K2, beta-alanine, creatine, curcumin, beta-alanine.
• All V5 cognitive additions except as flagged above: modafinil, bromantane, Adamax/Semax, taurine, apigenin, astaxanthin.
• BPC-157 / TB-500 healing peptides — different mechanism class, no documented interaction.
• Cerebrolysin — different mechanism class, no documented interaction.

• CYP enzymes: MB is a weak inhibitor of CYP1A2 and CYP3A4 in vitro; clinical relevance at oral biohacker doses is minimal. Not a major source of pharmacokinetic interactions.
• MAO-A inhibition: This is the dominant interaction surface — see SSRI/SNRI/MAOI/serotonergic-opioid list above. Dietary tyramine restriction is not typically required at oral nootropic doses (the MAO-A inhibition is partial/reversible and the dietary contribution to plasma tyramine is negligible at <50 mg MB/day) but a high-tyramine meal (aged cheese + cured meat + red wine) plus MB plus a sympathomimetic is theoretically a hypertensive-crisis stack. Dylan's zero-alcohol baseline + non-aged-cheese diet make this a non-issue practically.
• Serotonergic drugs: See black-box list above.
• Sympathomimetics (modafinil, bromantane, caffeine, pseudoephedrine): Theoretical additive blood-pressure effect. Not clinically observed at low MB doses + therapeutic stimulant doses. Worth occasional BP self-checks if Dylan stacks aggressively.
• NADPH-modulating drugs (high-dose vitamin C IV, high-dose alpha-lipoic acid): Shift MB toward reduced form; mechanism-relevant but no clinical interactions documented.
• Hormonal contraceptives: No documented interaction.
• Anticoagulants: Theoretical mild platelet-modulating effect; not clinically meaningful at biohacker doses.
• Statins: No documented interaction.

• G6PD (glucose-6-phosphate dehydrogenase) genotype + enzyme activity. This is the single most important pharmacogenomic / phenotypic check for MB. G6PD deficiency is X-linked (so primarily affects males), and MB precipitates oxidative hemolysis in deficient individuals — the same molecule that treats methemoglobinemia in normal G6PD patients causes hemolytic anemia in deficient ones. Population frequency: ~10% of African-American males, 5-15% in Mediterranean and Middle Eastern populations, ~0.5-1% in Northern European (Nordic/British) populations. Dylan's risk is low but not zero. 23andMe v5 chip covers some G6PD variants but not comprehensively; the gold-standard test is enzymatic G6PD activity, which is a routine add-on to a hematology panel. Add G6PD activity to Dylan's June 2026 bloodwork before any MB trial.
• MAO-A genotype (rs6323 / VNTR uVNTR). Low-activity MAO-A variants ("warrior gene" variants) have higher baseline serotonin/norepinephrine/dopamine; theoretically MB's MAO-A inhibition has different magnitude effect in low-activity carriers. No clinical data stratifies MB response by MAO-A genotype. Speculative.
• CYP2D6 phenotype. Poor metabolizers may have slower MB clearance and higher exposure. 23andMe will give a CYP2D6 call. Not a major dose driver but worth pulling.
• NQO1 (rs1800566 / C609T). Same variant relevant for idebenone — may be relevant for MB stacking. In NQO1 low-activity carriers, idebenone's NQO1-dependent activation is impaired; MB's NQO1-independent electron-carrier function would compensate. In NQO1 low-activity carriers, MB may be the better mitochondrial-bypass tool than idebenone. Speculative — no clinical data.
• APOE4 carriers. Speculative — mitochondrial-protective interventions theoretically more useful in APOE4-driven oxidative stress. No stratified data.

Bottom line: Get the G6PD result before first dose. NQO1 status modulates the relative idebenone-vs-MB choice. APOE4 strengthens the rationale.

For Dylan's recommendation: Health Natura USP Pharmaceutical Grade Methylene Blue 1% (30 mL), ~$25/bottle, ~$5-10/month at 10-30 mg/day dosing. Verify the bottle says "USP" or "Pharmaceutical Grade" — Health Natura's listing is explicit about this. Use a 1 mL graduated dropper or oral syringe; do not free-pour drops.

Important sourcing flag: the price differential between USP and non-USP is ~$20-30/year. There is zero economic incentive to use non-USP MB. Any vendor not explicitly stating USP / pharmaceutical-grade with COA-on-request is to be avoided.

Storage: dark glass bottle (light-sensitive), room temperature, away from sunlight. Stains anything it contacts — keep on hard non-porous surface, use a dedicated dropper.

• Baseline (before starting):

  • G6PD activity — the single most important pre-dose check. Add to June 2026 bloodwork as an explicit line item.
  • CBC + reticulocyte count — baseline to detect any hemolysis signal at week 4.
  • ALT, AST, GGT — hepatic baseline (not a major MB watch but standard).
  • Methemoglobin level — only relevant if any cyanosis symptoms develop; not routinely needed.
  • CYP2D6 phenotype, MAO-A rs6323, NQO1 rs1800566 — from 23andMe; modulate response prediction.
  • APOE genotype — from 23andMe; strengthens rationale if APOE4.
  • Subjective: cognitive-clarity rating at hour 4 of focused work (1-10).
  • Document urine color baseline; document oral mucosa state baseline (for self-comparison during use).

• During use (first 12 weeks, then every 6 months):

  • CBC + reticulocyte count at week 4 (only if any subjective fatigue / dyspnea — not routine).
  • Subjective cognitive-clarity rating at weeks 2, 4, 8, 12.
  • Note any unusual blood-pressure responses if stacking with stimulants.
  • Watch for any serotonergic-syndrome signs if any inadvertent serotonergic exposure (cough syrup, tramadol, etc.).

• Post-cycle (if cycled): No specific monitoring needed beyond the baseline panel at the next routine bloodwork.

For Dylan specifically: tie this into the June 2026 baseline panel he already has scheduled. Critical: G6PD activity must be on that panel. It is a low-cost add-on (often <$20). NQO1 / MAO-A / APOE genotypes derive from 23andMe.